Whole-brain radiotherapy can be delivered more safely to patients with brain metastases by avoiding the hippocampus, according to a randomized phase III NRG Oncology trial. Trial results were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Texas.

The first report of a large, international clinical trial shows that, for men who show signs of prostate cancer after ...

In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer ...

Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to a ...

October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and ...

At the 60th annual meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 at the Henry B. Gonzalez ...

Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The biodegradable SpaceOAR hydrogel is injected between the rectum and prostate to decrease a patient's exposure to rectal radiation and thereby reduce rectal radiation injury – one of the most common complications of prostate radiotherapy.